Designing a broad-spectrum multi-epitope vaccine against influenza A and Mycoplasma pneumoniae: an immunoinformatics approach

Introduction Influenza A and Mycoplasma pneumoniae (M. pneumoniae) are common respiratory pathogens, causing severe co-infections in clinical diseases. Current vaccines have failed to provide comprehensive protection against both of the pathogens, highlighting the requirement of integrated solution. Methods In this study, a novel dual-target multi-epitope vaccine was developed based on the immunoinformatics method. Based on the consistent sequences, we used the HA and NA proteins of influenza A virus, and the p1, p65, HMW1-3 proteins of M. pneumoniae to determine the immunodominant T- and B-cell epitopes. Results and Discussion The designed vaccine included 21 linear B-cell epitopes, 34 CTL epitopes and 19 HTL epitopes from influenza A virus and M. pneumoniae. The selection was based on antigenicity, immunogenicity, and alignment with previously validated epitopes. Structural and physicochemical assessments indicated that the vaccine had high stability, solubility, and minimal allergy risk. Molecular docking with TLR3 and TLR4 receptors revealed strong binding, suggesting robust immune activation. Population coverage analysis showed the vaccine could cover 97.07% of the global population, with high efficacy across key regions such as North America and East Asia. In this study, we provided an immunoinformatics approach for vaccine design.

• Publication year

  2026

• Venue

  Frontiers in Public Health

• Publication date

  2026-01-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3389/fpubh.2026.1671035PMID 41647741PMCID 12868154
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Design of a peptide-based vaccine against human respiratory syncytial virus using a reverse vaccinology approach: evaluation of immunogenicity, antigenicity, allergenicity, and toxicity

  2025cited by this paper
• Designing a T cell multi-epitope vaccine against hRSV with reverse vaccinology: An immunoinformatics approach.

  2025influential reference
• Designing a multi-epitope vaccine candidate against pandemic influenza a virus: an immunoinformatics and structural vaccinology approach

  2025cited by this paper
• The value of common blood parameters for the differential diagnosis of respiratory tract infections in children

  2025cited by this paper
• Toll-like receptor 4 pathway evolutionary trajectory and functional emergence

  2025cited by this paper
• Development and validation of an early diagnosis model for severe mycoplasma pneumonia in children based on interpretable machine learning

  2025cited by this paper
• HLA Class I and II allelic diversity among Ecuadorian transplant candidates: A comprehensive retrospective analysis.

  2025cited by this paper
• A computational approach to design a multiepitope vaccine against H5N1 virus

  2024cited by this paper
• An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza

  2024cited by this paper
• Respiratory tract barrier dysfunction in viral-bacterial co-infection cases

  2024cited by this paper
• Clinical Characteristics of Lung Consolidation with Mycoplasma pneumoniae Pneumonia and Risk Factors for Mycoplasma pneumoniae Necrotizing Pneumonia in Children

  2024cited by this paper
• Significance of respiratory virus coinfection in children with Mycoplasma pneumoniae pneumonia

  2024cited by this paper
• Research of recombinant influenza A virus as a vector for Mycoplasma pneumoniae P1a and P30a

  2024cited by this paper
• Rational design of a multi-epitope vaccine against heartland virus (HRTV) using immune-informatics, molecular docking and dynamics approaches.

  2024cited by this paper
• Application of peripheral blood routine parameters in the diagnosis of influenza and Mycoplasma pneumoniae

  2024influential reference
• Risk factors for pneumonia among children with coinfection of influenza A virus and Mycoplasma pneumoniae

  2024cited by this paper
• Design of a novel multiepitope vaccine with CTLA-4 extracellular domain against Mycoplasma pneumoniae: A vaccine-immunoinformatics approach.

  2024cited by this paper
• ΔA146Ply-HA stem protein immunization protects mice against influenza A virus infection and co-infection with Streptococcus pneumoniae.

  2023cited by this paper
• Vimentin Is an Attachment Receptor for Mycoplasma pneumoniae P1 Protein

  2023cited by this paper
• Beyond the state of the art of reverse vaccinology: predicting vaccine efficacy with the universal immune system simulator for influenza

  2023cited by this paper
• NEDD4 Regulated Pyroptosis Occurred from Co-infection between Influenza A Virus and Streptococcus pneumoniae

  2023cited by this paper
• Computational design and evaluation of mRNA- and protein-based conjugate vaccines for influenza A and SARS-CoV-2 viruses

  2023cited by this paper
• TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview

  2023cited by this paper
• In silico epitope-based vaccine design against influenza a neuraminidase protein: Computational analysis established on B- and T-cell epitope predictions

  2022cited by this paper
• Clinical features and outcome of influenza pneumonia in critically-ill immunocompromised patients

  2022cited by this paper
• Designing multi-epitope mRNA construct as a universal influenza vaccine candidate for future epidemic/pandemic preparedness.

  2022cited by this paper
• Evaluation of the consistence between the results of immunoinformatics predictions and real-world animal experiments of a new tuberculosis vaccine MP3RT

  2022cited by this paper
• Insight into the first multi-epitope-based peptide subunit vaccine against avian influenza A virus (H5N6): An immunoinformatics approach

  2022cited by this paper
• Cell damage and neutrophils promote the infection of Mycoplasma pneumoniae and inflammatory response.

  2022cited by this paper
• Clinical significance of respiratory virus coinfection in children with Mycoplasma pneumoniae pneumonia

  2022cited by this paper
• An immunoinformatics-based designed multi-epitope candidate vaccine (mpme-VAC/STV-1) against Mycoplasma pneumoniae

  2021cited by this paper
• Rational design of multimeric based subunit vaccine against Mycoplasma pneumonia: Subtractive proteomics with immunoinformatics framework.

  2021cited by this paper
• NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data

  2020cited by this paper
• Structural Basis for Designing Multiepitope Vaccines Against COVID-19 Infection: In Silico Vaccine Design and Validation

  2020cited by this paper
• Design of a multi-epitope vaccine against SARS-CoV-2 using immunoinformatics approach

  2020cited by this paper
• Peptide toxicity prediction.

  2015cited by this paper
• iMODS: internal coordinates normal mode analysis server

  2014cited by this paper
• Cross-reactive human B cell and T cell epitopes between influenza A and B viruses

  2013influential reference
• The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex

  2009cited by this paper
• Immunology of TLR-independent vaccine adjuvants.

  2009cited by this paper
• The molecular structure of the Toll-like receptor 3 ligand-binding domain.

  2005cited by this paper
• Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence.

  1990cited by this paper

• No citing papers are available for this paper.